IL151057A0 - Tamper-resistant oral opioid agonist formulations - Google Patents

Tamper-resistant oral opioid agonist formulations

Info

Publication number
IL151057A0
IL151057A0 IL15105701A IL15105701A IL151057A0 IL 151057 A0 IL151057 A0 IL 151057A0 IL 15105701 A IL15105701 A IL 15105701A IL 15105701 A IL15105701 A IL 15105701A IL 151057 A0 IL151057 A0 IL 151057A0
Authority
IL
Israel
Prior art keywords
tamper
opioid agonist
resistant oral
agonist formulations
oral opioid
Prior art date
Application number
IL15105701A
Other languages
English (en)
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22663996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL151057(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of IL151057A0 publication Critical patent/IL151057A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL15105701A 2000-02-08 2001-02-08 Tamper-resistant oral opioid agonist formulations IL151057A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18136900P 2000-02-08 2000-02-08
PCT/US2001/004346 WO2001058451A1 (fr) 2000-02-08 2001-02-08 Formes orales inviolables d'agonistes de l'opioide

Publications (1)

Publication Number Publication Date
IL151057A0 true IL151057A0 (en) 2003-04-10

Family

ID=22663996

Family Applications (5)

Application Number Title Priority Date Filing Date
IL15105701A IL151057A0 (en) 2000-02-08 2001-02-08 Tamper-resistant oral opioid agonist formulations
IL151057A IL151057A (en) 2000-02-08 2002-08-01 Oral administration vehicles of an opioid agonist
IL181356A IL181356A (en) 2000-02-08 2007-02-15 Oral administration vehicles of an opioid agonist
IL204761A IL204761A (en) 2000-02-08 2010-03-25 Oral compositions containing opioid antagonist and hydrophobic agent coated with opioid agonist
IL215132A IL215132A0 (en) 2000-02-08 2011-09-13 Tamper resistant oral opioid agonist formulations

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL151057A IL151057A (en) 2000-02-08 2002-08-01 Oral administration vehicles of an opioid agonist
IL181356A IL181356A (en) 2000-02-08 2007-02-15 Oral administration vehicles of an opioid agonist
IL204761A IL204761A (en) 2000-02-08 2010-03-25 Oral compositions containing opioid antagonist and hydrophobic agent coated with opioid agonist
IL215132A IL215132A0 (en) 2000-02-08 2011-09-13 Tamper resistant oral opioid agonist formulations

Country Status (35)

Country Link
US (15) US6696088B2 (fr)
EP (6) EP2283842B1 (fr)
JP (10) JP2003522146A (fr)
KR (2) KR20020071032A (fr)
CN (3) CN100563656C (fr)
AP (1) AP1665A (fr)
AT (1) ATE431145T1 (fr)
AU (2) AU776904B2 (fr)
BG (1) BG65828B1 (fr)
BR (2) BR0108379A (fr)
CA (1) CA2400567C (fr)
CY (2) CY1109270T1 (fr)
CZ (1) CZ299991B6 (fr)
DE (1) DE60138706D1 (fr)
DK (5) DK2277521T3 (fr)
EA (1) EA004876B1 (fr)
EE (1) EE05171B1 (fr)
ES (5) ES2539904T3 (fr)
GE (1) GEP20053614B (fr)
HK (3) HK1051487A1 (fr)
HU (2) HU229705B1 (fr)
IL (5) IL151057A0 (fr)
ME (1) MEP48308A (fr)
MX (2) MXPA02007690A (fr)
NO (2) NO324717B1 (fr)
NZ (1) NZ520554A (fr)
OA (1) OA12215A (fr)
PL (1) PL210845B1 (fr)
PT (6) PT2517710E (fr)
RS (1) RS50407B (fr)
SI (5) SI2517710T1 (fr)
SK (1) SK287107B6 (fr)
TW (1) TWI292317B (fr)
UA (1) UA79069C2 (fr)
WO (2) WO2001058447A1 (fr)

Families Citing this family (329)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA53774C2 (uk) * 1997-12-22 2003-02-17 Еро-Селтік, С.А. Спосіб запобігання зловживанню лікарськими формами, що містять опіоїди
RU2241458C2 (ru) 1997-12-22 2004-12-10 Эро-Селтик, С.А. Комбинации агонист/антагонист опиоида
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2295043A1 (fr) 1999-10-29 2011-03-16 Euro-Celtique S.A. Formulations d'hydrocodone à liberation lente
SI2517710T1 (sl) 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
KR101167465B1 (ko) 2000-10-30 2012-07-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US7858118B2 (en) * 2001-04-11 2010-12-28 Galephar Pharmaceutical Research, Inc. Extended release composition containing Tramadol
JP4522652B2 (ja) * 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド 乱用防止制御放出オピオイド投薬形態
WO2002092059A1 (fr) * 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Forme posologique d'opioides empechant la consommation abusive
US7968119B2 (en) * 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
PL208484B1 (pl) * 2001-07-06 2011-05-31 Penwest Pharmaceuticals Company Sposoby wytwarzania preparatów oksymorfonu o przedłużonym uwalnianiu
WO2003004031A1 (fr) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Administration parenterale de 6-hydroxy-oxymorphone destinee a etre utilisee en tant qu'analgesique
AU2002316738B2 (en) * 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
MXPA04001210A (es) 2001-08-06 2004-07-08 Euro Celtique Sa Formulaciones de agonista opioide con antagonista liberable y aislado.
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030049317A1 (en) * 2001-08-30 2003-03-13 Lindsay David R. Method and composition for reducing the danger and preventing the abuse of controlled release pharmaceutical formulations
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
PT1436012T (pt) 2001-10-18 2018-03-27 Nektar Therapeutics Conjugados poliméricos de antagonistas de opióides
EP1450824A4 (fr) * 2001-11-02 2005-09-28 Elan Corp Plc Composition pharmaceutique
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
ES2500117T3 (es) * 2002-02-22 2014-09-30 Shire Llc Novedosos compuestos farmacéuticos de liberación sostenida para prevenir el abuso de sustancias controladas
CN1652752A (zh) * 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 盐酸纳曲酮组合物
GB0206505D0 (en) * 2002-03-19 2002-05-01 Euro Celtique Sa Pharmaceutical combination
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
AU2003220551A1 (en) 2002-03-26 2003-10-13 Euro-Celtique S.A. Sustained-release gel coated compositions
JP4620355B2 (ja) 2002-04-05 2011-01-26 ユーロ−セルティーク エス．エイ． 活性化合物の持続、不変及び独立放出のためのマトリクス
AU2003246792B2 (en) 2002-04-09 2008-08-28 Flamel Ireland Limited Oral suspension of active principle microcapsules
IL164221A0 (en) * 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
CN1720028A (zh) 2002-04-23 2006-01-11 阿尔扎公司 降低了滥用可能的经皮止痛系统
US20040156844A1 (en) * 2002-05-22 2004-08-12 Curtis Wright Tamper resistant oral dosage form
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
AU2003281182A1 (en) * 2002-07-11 2004-02-02 Taiho Pharmaceutical Co., Ltd. Composition for nasal absorption
PE20040134A1 (es) 2002-07-25 2004-03-06 Pharmacia Corp Forma de dosificacion de una vez al dia de pramipexol
DE10237056A1 (de) * 2002-08-09 2004-03-04 Grünenthal GmbH Opiod-Rezeptor-Antagonisten in Transdermalen Systemen mit Buprenorphin
EP1542658B1 (fr) 2002-08-15 2010-12-29 Euro-Celtique S.A. Compositions pharmaceutiques contenant un analgésique opioide
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
CN1703200B (zh) * 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
EP1551402A4 (fr) * 2002-09-23 2009-05-27 Verion Inc Compositions pharmaceutiques n'induisant pas l'abus
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
EP1555996A2 (fr) 2002-10-31 2005-07-27 Euro-Celtique Identification d'un article pharmaceutique
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US7524515B2 (en) 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
DE10305137A1 (de) * 2003-02-07 2004-08-26 Novosis Ag Transdermale therapeutische Abgabesysteme mit einem Butenolid
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
MXPA05011071A (es) * 2003-04-21 2005-12-12 Euro Celtique Sa Forma de dosificacion resistente a la alteracion que comprende particulas co-extrusionadas de agente adverso y proceso de fabricacion de las misma.
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
BRPI0409945A (pt) * 2003-04-30 2006-04-25 Purdue Pharma Lp forma de dosagem resistente à alteração
CA2529984C (fr) 2003-06-26 2012-09-25 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) * 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
KR20120104199A (ko) * 2003-08-06 2012-09-20 그뤼넨탈 게엠베하 남용 방지 제형
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2005032555A2 (fr) * 2003-09-25 2005-04-14 Euro-Celtique S.A. Combinaisons pharmaceutiques d'hydrocodone et de naltrexone
EP1663229B1 (fr) * 2003-09-25 2010-04-14 Euro-Celtique S.A. Combinaisons pharmaceutiques d'hydrocodone et de naltrexone
US20050245557A1 (en) * 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
CA2542395A1 (fr) * 2003-10-15 2005-04-28 Pain Therapeutics, Inc. Procedes et produits convenant au traitement d'etats arthritiques, d'inflammation associee a un etat chronique ou une douleur chronique
CA2543610A1 (fr) 2003-10-30 2005-05-19 Alza Corporation Systemes analgesiques transdermiques reduisant les risques d'abus de consommation
PL1691892T3 (pl) * 2003-12-09 2007-07-31 Euro Celtique Sa Odporna na fizyczne manipulowanie, współwytłaczana postać dawkowania zawierająca środek aktywny i środek przeciwdziałający oraz sposób wytwarzania tej postaci
US8883204B2 (en) 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
SI2074989T1 (sl) * 2004-02-23 2014-02-28 Euro-Celtique S.A. Naprava za transdermalno dajanje opioida, varna pred zlorabo
DE602005012244D1 (de) * 2004-03-30 2009-02-26 Euro Celtique Sa Manipulationssichere dosierform mit einem adsorbens und einem adversen mittel
TW201509943A (zh) * 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
EP1604667A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement des impatiences des membres inférieurs
EP1604666A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CA2576386A1 (fr) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Preparation d'une pastille a autorisation de sortie elargie, contenant du pramipexole ou un sel de pramipexole pharmaceutiquement acceptable, procede de fabrication et d'utilisation de cette pastille
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
US7226619B1 (en) 2004-09-07 2007-06-05 Pharmorx Inc. Material for controlling diversion of medications
US7827983B2 (en) * 2004-12-20 2010-11-09 Hewlett-Packard Development Company, L.P. Method for making a pharmaceutically active ingredient abuse-prevention device
AP2274A (en) 2005-01-28 2011-08-19 Euro Celtiques Sa Alcohol resistant dosage forms.
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
FR2889810A1 (fr) * 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
EP1695700A1 (fr) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Forme posologique contenant de l'oxycodone et de la naloxone
EP1702558A1 (fr) 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
PL1895994T3 (pl) 2005-05-13 2011-02-28 Alza Corp Wielowarstwowy system podawania leków z barierą zabezpieczającą przed wypływaniem materiału ze zbiornika
CA2608361A1 (fr) * 2005-05-13 2006-11-23 Alpharma, Inc. Formulations de sulfate de morphine
AU2006247357B2 (en) * 2005-05-13 2012-03-08 Alpharma Pharmaceuticals Llc Morphine sulfate formulations
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
WO2006133733A1 (fr) * 2005-06-13 2006-12-21 Flamel Technologies Forme posologique orale comportant un systeme anti-abus
AU2006275476A1 (en) * 2005-08-01 2007-02-08 Alpharma Inc. Alcohol resistant pharmaceutical formulations
KR101158162B1 (ko) 2005-08-02 2012-06-19 솔-겔 테크놀로지스 리미티드 수 불용성 성분을 금속 산화물로 피복시키는 방법
US9125833B2 (en) * 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
WO2007087452A2 (fr) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Formulations à libération prolongée empêchant l'usage abusif et méthodes d'utilisation de celles-ci
US8329744B2 (en) * 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
CA2630624C (fr) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions et procedes d'augmentation de la sensibilite a l'insuline
BRPI0619806A2 (pt) * 2005-12-13 2011-10-18 Biodelivery Sciences Int Inc dispositivo para fornecimento de fármacos transmucosal resistente ao abuso
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1810678A1 (fr) * 2006-01-19 2007-07-25 Holger Lars Hermann Utilisation de morphine et naloxone pour la substitution de médicaments
EP1810714A1 (fr) * 2006-01-19 2007-07-25 Holger Lars Hermann Utilisation d'une association d'héroine et de naloxone pour la substitution de drogues
EP1991207A2 (fr) * 2006-01-21 2008-11-19 Abbott GmbH & Co. KG Forme dosifiée et méthode d'administration de drogues toxicomanogènes
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
US7939567B2 (en) * 2006-02-24 2011-05-10 Blue Blood Biotech Corp. Dextromethorphan-based method for treating acne
FR2898056B1 (fr) 2006-03-01 2012-01-20 Ethypharm Sa Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
WO2007109104A2 (fr) 2006-03-16 2007-09-27 Tris Pharma, Inc. Formulations a liberation modifiee contenant des complexes medicament - resine echangeuse d'ions
GB0606124D0 (en) * 2006-03-28 2006-05-03 Reckitt Benckiser Healthcare Buprenorphine derivatives and uses thereof
EP2007360B1 (fr) * 2006-04-03 2014-11-26 Isa Odidi Dispositif d'administration à libération commandée comprenant un enrobage organosol
US20100010029A1 (en) * 2006-05-03 2010-01-14 Kowa Phamaceuticals America, Inc. Acute Pain Medications Based on Fast Acting Diclofenac-Opioid Combinations
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
DK2719378T3 (en) * 2006-06-19 2016-10-17 Alpharma Pharmaceuticals Llc pharmaceutical compositions
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
WO2008011596A2 (fr) * 2006-07-21 2008-01-24 Lab International Srl Système de délivrance hydrophile empêchant les utilisations abusives
HUE027395T2 (hu) * 2006-07-21 2016-10-28 Biodelivery Sciences Int Inc Eszközök nyálkahártyán keresztül történõ bejuttatására, javított felszívódással
AU2011205222B2 (en) * 2006-07-21 2014-02-27 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP1897543A1 (fr) 2006-08-30 2008-03-12 Euro-Celtique S.A. Gaufre de buprénorphine pour la thérapie de substitution
WO2008027442A2 (fr) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Formulations pharmaceutiques orales anti-abus à base d'opioïdes et procédé d'utilisation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8187636B2 (en) * 2006-09-25 2012-05-29 Atlantic Pharmaceuticals, Inc. Dosage forms for tamper prone therapeutic agents
EP2073797A2 (fr) * 2006-10-11 2009-07-01 Alpharma, Inc. Compositions pharmaceutiques
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
ES2439581T3 (es) 2006-12-04 2014-01-23 Orexo Ab Nueva composición farmacéutica no susceptible de abuso que comprende opioides
WO2008093346A2 (fr) 2007-02-01 2008-08-07 Sol-Gel Technologies Ltd. Compositions d'application topique comprenant un peroxyde et un rétinoïde
GB2447014A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
ATE476176T1 (de) 2007-03-02 2010-08-15 Farnam Co Inc Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
CA2923102C (fr) 2007-08-13 2019-10-15 Abuse Deterrent Pharmaceutical Llc Medicaments resistant aux abus, procedes d'utilisation et de fabrication
SI2197429T1 (sl) * 2007-09-03 2016-09-30 Nanotherapeutics, Inc. Sestavki iz delcev za vnos slabo topnih zdravil
CA2709905A1 (fr) * 2007-12-17 2009-06-25 Alfred Liang Composition d'oxycodone a l'epreuve d'un usage abusif
AU2015200313B2 (en) * 2007-12-17 2016-12-01 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
AU2008343267A1 (en) * 2007-12-17 2009-07-09 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
CA2709903A1 (fr) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Compositions opioides orales comportant un antagoniste opioide
US20100266645A1 (en) * 2007-12-17 2010-10-21 Alfred Liang Pharmaceutical compositions
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2707980C (fr) 2007-12-17 2015-05-12 Labopharm Inc. Formulation a liberation controlee evitant les utilisations impropres
MX2010008138A (es) 2008-01-25 2010-08-10 Gruenenthal Gmbh Forma de dosis farmaceutica.
WO2009106831A2 (fr) * 2008-02-28 2009-09-03 Syntropharma Limited Composition pharmaceutique
RU2508092C2 (ru) 2008-05-09 2014-02-27 Грюненталь Гмбх Способ получения твердой лекарственной формы, в частности таблетки для фармацевтического применения, и способ получения прекурсора твердой лекарственной формы, в частности таблетки
EP2303025A4 (fr) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Procédés pour traiter des pathologies des graisses viscérales
PE20110422A1 (es) * 2008-07-07 2011-07-01 Euro Celtique Sa Composicion farmaceutica que comprende antagonistas opioides
WO2010044842A1 (fr) * 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Formes pharmaceutiques orales inviolables contenant un agent embolisant
CN102281876A (zh) 2008-10-30 2011-12-14 格吕伦塔尔有限公司 新型有效的他喷他多剂型
WO2010066034A1 (fr) * 2008-12-12 2010-06-17 Paladin Labs Inc. Préparation de méthadone
US8486449B2 (en) 2008-12-16 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
AU2009332963B2 (en) 2008-12-31 2015-02-05 Upsher-Smith Laboratories, Llc Opioid-containing oral pharmaceutical compositions and methods
EP3045043B1 (fr) * 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Compositions pharmaceutiques orales à libération prolongée de 3-hydroxy-n-méthylmorphinane et procédé d'utilisation
PT2405915T (pt) 2009-03-10 2019-01-29 Euro Celtique Sa Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona
AU2010238925A1 (en) * 2009-04-22 2011-12-15 Phoeme Gmbh Particulate pharmaceutical composition having an opioid and an opioid antagonist
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
WO2011009604A1 (fr) 2009-07-22 2011-01-27 Grünenthal GmbH Forme galénique inviolable stabilisée à l’oxydation
AR077493A1 (es) 2009-07-22 2011-08-31 Gruenenthal Gmbh Composicion farmaceutica extruida en caliente con liberacion controlada. procedimiento de preparacion
BR112012008317A2 (pt) 2009-09-17 2016-03-22 Upsher Smith Lab Inc produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
CN102821757B (zh) 2010-02-03 2016-01-20 格吕伦塔尔有限公司 通过挤出机制备粉末状药物组合物
US9277748B2 (en) 2010-03-12 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Agonist/antagonist compositions and methods of use
ES2408343B2 (es) 2010-05-10 2014-07-17 Euro-Celtique, Sa Composiciones farmacéuticas que comprenden hidromorfona y naloxona
JP5838199B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を含まない顆粒およびその顆粒を含む錠剤の製造
NZ603170A (en) * 2010-05-10 2015-04-24 Euro Celtique Sa Combination of active loaded granules with additional actives
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク． メトプロロールを含むアルコール耐性持続放出性経口剤形
WO2012028319A1 (fr) 2010-09-02 2012-03-08 Grünenthal GmbH Forme pharmaceutique inviolable comportant un sel inorganique
AR082862A1 (es) 2010-09-02 2013-01-16 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico
DE102010048883A1 (de) 2010-10-19 2012-04-19 Lars Holger Hermann Verwendung von Buprenorphin zum Abususschutz von Opiat-Vollagonisten sowie entsprechende pharmazeutische Zusammensetzungen
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
JP2012087101A (ja) * 2010-10-21 2012-05-10 Holger Hermann Lars オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
ME02874B (fr) 2010-12-22 2018-04-20 Purdue Pharma Lp Formes posologiques à libération contrôlée enchâssées et inviolables
AU2011346758C1 (en) 2010-12-23 2015-09-03 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
KR101618929B1 (ko) * 2010-12-28 2016-05-09 유로-셀티큐 에스.에이. 파킨슨병의 치료에 있어서 오피오이드 효능제와 오피오이드 길항제의 조합물
CN102068697B (zh) * 2010-12-30 2013-10-16 宜昌人福药业有限责任公司 含有阿片类镇痛剂和阿片受体拮抗剂的药用组合物
SG191872A1 (en) 2011-02-02 2013-08-30 Alpharma Pharmaceuticals Llc Pharmaceutical composition comprising opioid agonist and sequestered antagonist
BR112013021026A2 (pt) 2011-02-17 2016-10-11 Qrxpharma Ltd tecnologia para prevenção de abuso de formas de dosagem sólidas
EP2726065A4 (fr) * 2011-06-30 2014-11-26 Neos Therapeutics Lp Formes médicamenteuses résistant à l'abus
NO2736497T3 (fr) 2011-07-29 2018-01-20
KR20140053159A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
ES2660116T3 (es) 2011-08-18 2018-03-20 Biodelivery Sciences International, Inc. Dispositivos mucoadhesivos resistentes al uso inadecuado para la administración de buprenorfina
CA2834327C (fr) 2011-09-19 2017-05-30 Orexo Ab Nouvelle composition pharmaceutique resistante a l'utilisation abusive pour le traitement d'une dependance aux opioides
CN104010630A (zh) * 2011-12-09 2014-08-27 普渡制药公司 包含聚(ε-己内酯)和聚氧乙烯的药物剂型
PE20142341A1 (es) 2011-12-12 2015-01-17 Lohmann Therapie Syst Lts Sistema de administracion transdermica
SG10202012743WA (en) * 2011-12-21 2021-01-28 Biodelivery Sciences Int Inc Transmucosal drug delivery devices for use in chronic pain relief
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
WO2013127831A1 (fr) 2012-02-28 2013-09-06 Grünenthal GmbH Forme pharmaceutique inviolable comprenant un composé pharmacologiquement actif et un polymère anionique
US9687445B2 (en) 2012-04-12 2017-06-27 Lts Lohmann Therapie-Systeme Ag Oral film containing opiate enteric-release beads
PE20150020A1 (es) 2012-04-17 2015-01-28 Purdue Pharma Lp Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9616078B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9655908B2 (en) 2012-05-14 2017-05-23 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9675626B2 (en) 2012-05-14 2017-06-13 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9211257B2 (en) 2012-05-14 2015-12-15 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9662343B2 (en) 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9289441B2 (en) 2014-08-08 2016-03-22 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US8865757B1 (en) 2014-05-28 2014-10-21 Antecip Bioventures Ii Llp Therapeutic compositions comprising imidazole and imidazolium compounds
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9669040B2 (en) 2012-05-14 2017-06-06 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US9427403B2 (en) 2012-05-14 2016-08-30 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US8802658B2 (en) 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
PL3730132T3 (pl) 2012-06-06 2022-10-10 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
CA2877774C (fr) 2012-07-12 2017-07-18 Mallinckrodt Llc Compositions pharmaceutiques de dissuasion d'abus a liberation prolongee
US9687465B2 (en) 2012-11-27 2017-06-27 Sol-Gel Technologies Ltd. Compositions for the treatment of rosacea
KR101659983B1 (ko) * 2012-12-31 2016-09-26 주식회사 삼양바이오팜 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
BR112015017451B1 (pt) 2013-02-05 2023-01-10 Purdue Pharma L.P. Formulações farmacêuticas resistentes à violação
WO2014146093A2 (fr) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Compositions anti-abus et méthodes d'utilisation
US9517208B2 (en) 2013-03-15 2016-12-13 Purdue Pharma L.P. Abuse-deterrent dosage forms
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
ITTO20130284A1 (it) * 2013-04-09 2014-10-10 Fond Istituto Italiano Di Tecnologia Procedimento per la produzione di microparticelle polimeriche sagomate
BR112015026549A2 (pt) * 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
AP2015008920A0 (en) 2013-06-04 2015-12-31 Lohmann Therapie Syst Lts Transdermal delivery system
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
JP2016535778A (ja) 2013-10-31 2016-11-17 シーマ・ラブス・インコーポレーテッド 乱用抑止性剤形
MX2016006279A (es) 2013-11-13 2016-09-07 Euro Celtique Sa Hidromorfona y naloxona para el tratamiento del dolor y el sindrome de disfuncion intestinal opiacea.
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CN110755372A (zh) 2014-03-14 2020-02-07 欧皮安特制药有限公司 适于经鼻递送药物产品、用于鼻内给予的药用组合物及其用途
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
EP3142646A1 (fr) 2014-05-12 2017-03-22 Grünenthal GmbH Formulation pour capsule à libération immédiate résistant aux manipulations illicites comprenant du tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
CA2910865C (fr) 2014-07-15 2016-11-29 Isa Odidi Compositions et methodes destines a reduire les surdoses
US10493027B2 (en) 2014-08-07 2019-12-03 Mucodel Pharma Llc Chemically stable compositions of a pharmaceutical active agent in a multi- chambered delivery system for mucosal delivery
US9682039B2 (en) * 2014-08-07 2017-06-20 Mucodel Pharma Llc Chemically stable and oromucosally absorbable gel compositions of a pharmaceutical active agent in a multi-chambered delivery system
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
WO2016091805A2 (fr) * 2014-12-08 2016-06-16 Develco Pharma Schweiz Ag Monopréparation de naloxone et comprimé multicouche
WO2016094358A1 (fr) 2014-12-08 2016-06-16 Cima Labs Inc. Formes galéniques en granulés à libération immédiate, à effet anti-abus
FR3032353B1 (fr) 2015-02-06 2017-03-10 Jacques Seguin Composition pharmaceutique et dispositif pour le traitement de la douleur
EP3285745A1 (fr) 2015-04-24 2018-02-28 Grünenthal GmbH Forme galénique inviolable avec libération immédiate et résistance à l'extraction par solvant.
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
EP3344997B1 (fr) * 2015-08-31 2020-11-18 Regents of the University of Minnesota Modulateurs des récepteurs opioïdes et leur utilisation
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
CA2997668C (fr) * 2015-09-09 2021-06-01 Micell Technologies, Inc. Systeme d'administration de medicaments comprenant un support biodegradable avec des particules de petite taille et un medicament sousforme de poudre seche
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
GB201520390D0 (en) * 2015-11-19 2016-01-06 Euro Celtique Sa Composition
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2017222575A1 (fr) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Procédé de préparation de formulations orales dissuasives d'abus plus stables
CA2972220C (fr) 2016-06-29 2023-01-24 Disposerx, Inc. Elimination de medicaments
WO2018012627A1 (fr) * 2016-07-15 2018-01-18 シャープ株式会社 Appareil de soufflage d'air et climatiseur
WO2018208241A1 (fr) * 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation et optimisation de comprimés à libération contrôlée de sulfate de morphine
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
WO2019074829A1 (fr) 2017-10-09 2019-04-18 Rhodes Pharmaceuticals L.P. Compositions pharmaceutiques à base de résinate, et leurs procédés de fabrication et d'utilisation
EP3473246A1 (fr) 2017-10-19 2019-04-24 Capsugel Belgium NV Formulations anti-abus à libération immédiate
US10624856B2 (en) 2018-01-31 2020-04-21 Dharma Laboratories LLC Non-extractable oral solid dosage forms
CN109232748B (zh) * 2018-09-26 2019-06-11 哈尔滨工业大学 多位点修饰的脑啡肽与神经降压素(8-13)相偶联的环化杂合肽及其合成方法和应用
WO2020159901A1 (fr) * 2019-01-31 2020-08-06 Relmada Therapeutics, Inc. Préparations d'opioïdes résistantes à l'abrasion qui résistent à l'utilisation abusive et comprennent un antagoniste des opioïdes séquestré
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
EP3996691A1 (fr) * 2019-07-10 2022-05-18 Intas Pharmaceuticals Ltd. Formulation de naltrexone
IT201900013473A1 (it) * 2019-07-31 2021-01-31 Vetagro Int S R L Composizioni comprendenti amminoacidi e un ulteriore componente per l'apporto di amminoacidi ad un animale monogastrico quale uomo o maiale
EP3936112A1 (fr) * 2020-07-07 2022-01-12 Occlugel Microsphères dégradables hydrophiles pour administration de buprénorphine
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition
WO2023146983A1 (fr) * 2022-01-26 2023-08-03 Aardvark Therapeutics, Inc. Formulation de naltrexone orale à libération prolongée de résine liquide pour le traitement de troubles liés à l'autisme

Family Cites Families (230)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US316889A (en) 1885-04-28 Soil pulverizer and leveler
US2770569A (en) 1952-08-01 1956-11-13 Hoffmann La Roche Analgesic compositions
US3493657A (en) 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3879555A (en) 1970-11-16 1975-04-22 Bristol Myers Co Method of treating drug addicts
US3676557A (en) 1971-03-02 1972-07-11 Endo Lab Long-acting narcotic antagonist formulations
GB1390772A (en) * 1971-05-07 1975-04-16 Endo Lab Oral narcotic composition
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916889A (en) 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4237140A (en) 1979-05-18 1980-12-02 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetaminophen
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
IE49324B1 (en) 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4587118A (en) 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
US4401672A (en) 1981-10-13 1983-08-30 Regents Of The University Of Minnesota Non-addictive narcotic antitussive preparation
US4608376A (en) 1981-10-16 1986-08-26 Carolyn McGinnis Opiate agonists and antagonists
DE3381877D1 (de) 1982-03-16 1990-10-18 Univ Rockefeller Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen.
US4987136A (en) 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4443428A (en) 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4451470A (en) 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4803208A (en) 1982-09-30 1989-02-07 Sloan-Kettering Institute For Cancer Research Opiate agonists and antagonists
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
DE3434946A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen Diarylacetylene, ihre herstellung und verwendung
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
CA1267092A (fr) 1985-02-25 1990-03-27 Martin D. Hynes Compose analgesique contenant de la codeine
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
GB8521350D0 (en) 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
ATE84717T1 (de) 1985-09-06 1993-02-15 Baker Cummins Pharma Verwendung von 6-methylen-6-desoxy-nus850906
US4760069A (en) 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4889860A (en) 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
DE219243T1 (de) 1985-10-11 1987-09-24 Monolithic Memories, Inc., Santa Clara, Calif., Us Verfahren zur herstellung eines bipolaren transistors.
US4730048A (en) 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ES2058111T3 (es) 1986-06-10 1994-11-01 Euro Celtique Sa Composicion de liberacion controlada de dihidrocodeina.
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US5356900A (en) 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
DE3636075A1 (de) * 1986-10-23 1988-04-28 Merck Patent Gmbh Kosmetische zubereitungen
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
GB8628728D0 (en) 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
US4831781A (en) * 1987-11-02 1989-05-23 Dayton Extruded Plastics, Inc. Window assembly of rigid plastics material
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
JPH01279895A (ja) * 1988-01-20 1989-11-10 Baker Cummins Pharmaceut Inc オピオイド拮抗剤のグルクロン酸誘導体
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US4873076A (en) 1988-04-29 1989-10-10 Baker Cummins Pharmaceuticals, Inc. Method of safely providing anesthesia or conscious sedation
GB8813064D0 (en) 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
EP0352361A1 (fr) * 1988-07-29 1990-01-31 The Rockefeller University Procédé pour traiter des patients souffrant de douleurs chroniques ou de toux chronique
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
CA2002492A1 (fr) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Compose pharmaceutique contenant une resine echangeuse d'ions
US5260331A (en) 1989-01-02 1993-11-09 John Wyeth & Brother Limited Composition for treating depression with (S- or O-heteroaryl)alkyl amines
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5096715A (en) 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5086058A (en) 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
FR2663818B1 (fr) * 1990-06-29 1993-07-09 Rhone Poulenc Nutrition Animale Procede de preparation de granules de principes actifs par extrusion.
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
CZ284993B6 (cs) * 1991-03-29 1999-04-14 Eli Lilly And Company Derivát piperidinu
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
HU219332B (hu) 1991-09-06 2001-03-28 Mcneilab Inc Transz-(+)-2-[(dimetil-amino)-metil]-1-(3-metoxi-fenil)-ciklohexanolt és acetaminofent tartalmazó szinergetikus gyógyszerkészítmények
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5225440A (en) 1991-09-13 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
US5226331A (en) 1991-10-03 1993-07-13 General Electric Company Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9203689D0 (en) 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
GB9204354D0 (en) 1992-02-28 1992-04-08 Biokine Tech Ltd Compounds for medicinal use
CA2138026C (fr) 1992-06-22 2003-09-09 Eckard Weber Nouveau 1,4-dihydroquinoxaline-2,3-diones et leur utilisation en tant qu'antagonistes des recepteurs de la glycine
US5352680A (en) 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
JP2563100Y2 (ja) 1992-08-05 1998-02-18 日本精工株式会社 シートベルト用リトラクター
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
EP0668764A1 (fr) 1992-09-21 1995-08-30 QIN, Bo-yi Procedes d'identification et d'utilisation d'analgesiques opioides de faible dependance ou de non dependance
US5512578A (en) 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5633259A (en) 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5585348A (en) 1993-02-10 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
CA2115792C (fr) 1993-03-05 2005-11-01 David J. Mayer Methode de traitement de la douleur
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4325465B4 (de) 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
US5411965A (en) 1993-08-23 1995-05-02 Arizona Board Of Regents Use of delta opioid receptor antagonists to treat cocaine abuse
GB9319568D0 (en) 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
EP0647448A1 (fr) 1993-10-07 1995-04-12 Euroceltique S.A. Compositions pharmaceutiques administrables par voie oral à base d'opioides analgésiques à action prolongée
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5376662A (en) 1993-12-08 1994-12-27 Ockert; David M. Method of attenuating nerve injury induced pain
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5451408A (en) 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs
US5475995A (en) 1994-05-16 1995-12-19 Livingston; George G. Truck spare tire locking rod
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
ATE214276T1 (de) * 1994-09-19 2002-03-15 Du Pont Pharm Co Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
EP2301562B1 (fr) 1994-12-12 2013-04-17 Omeros Corporation Solution d'irrigation et utilisation de celle-ci pour inhiber périopérativement la douleur, l'inflammation et/ou les spasmes
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
ATE267587T1 (de) 1995-06-09 2004-06-15 Euro Celtique Sa Formulierungen und verfahren für eine verlängerte lokalanästhesie
GB9517883D0 (en) 1995-09-01 1995-11-01 Euro Celtique Sa Improved pharmaceutical ion exchange resin composition
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
US5998434A (en) * 1995-12-06 1999-12-07 Eli Lilly And Company Composition for treating pain
EP0914097B1 (fr) * 1996-03-12 2002-01-16 Alza Corporation Composition et forme galenique contenant un antagoniste des opioides
JPH11505547A (ja) 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置
US6103258A (en) 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
DE19654468C1 (de) 1996-12-27 1998-01-22 Lohmann Therapie Syst Lts Extrem flexibles, dermal oder transdermal wirkendes Pflaster und Verfahren zu seiner Herstellung
PL190293B1 (pl) 1997-02-14 2005-11-30 Goedecke Ag Sposób stabilizowania naloksonu i jego soli, stały półstały lub ciekły lek, zawierający nalokson i jego sole oraz zastosowanie środków stabilizujących do zapobiegania dimeryzacji naloksonu
DE29719704U1 (de) 1997-02-14 1998-01-22 Goedecke Ag Stabile Zubereitungen von Naloxonhydrochlorid
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5780479A (en) 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
US6120806A (en) 1997-06-25 2000-09-19 Whitmire; David R. Oral formulations for controlled release of alcohol deterrents
AU8293498A (en) 1997-07-02 1999-01-25 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
ATE210983T1 (de) 1997-11-03 2002-01-15 Stada Arzneimittel Ag Stabilisiertes kombinationsarzneimittel enthaltend naloxone und ein opiatanalgetikum
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
UA53774C2 (uk) * 1997-12-22 2003-02-17 Еро-Селтік, С.А. Спосіб запобігання зловживанню лікарськими формами, що містять опіоїди
RU2241458C2 (ru) 1997-12-22 2004-12-10 Эро-Селтик, С.А. Комбинации агонист/антагонист опиоида
US6248691B1 (en) 1998-02-10 2001-06-19 Corning Incorporated Method of making mesoporous carbon
BR9911071A (pt) * 1998-05-27 2001-02-06 Euro Celtique Sa Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépticos e/ou agentes promotores da cura de feridas no trato respiratório superior e/ou no ouvido
DE19859636A1 (de) 1998-12-23 2000-06-29 Hexal Ag Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff
FR2787715B1 (fr) 1998-12-23 2002-05-10 Synthelabo Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables
US6312949B1 (en) 1999-03-26 2001-11-06 The Salk Institute For Biological Studies Regulation of tyrosine hydroxylase expression
US6765010B2 (en) 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
AU776567B2 (en) 1999-11-01 2004-09-16 Evans, Brian K Composition for treatment of constipation and irritable bowel syndrome
DK1244447T3 (da) 1999-11-29 2007-04-23 Adolor Corp Nye fremgangsmåder og sammensætninger indeholdende opioider og deres antagonister
WO2001052851A1 (fr) 2000-01-22 2001-07-26 Albert Shulman Methodes de traitement d'abus de substances
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
SI2517710T1 (sl) 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
CA2403252A1 (fr) 2000-03-15 2001-09-20 Wolfgang Sadee Antagonistes neutres et utilisation de ces derniers dans le traitement de l'abus des drogues
WO2001085257A2 (fr) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Compositions d'antagoniste opioide et formes de dosage
AU2001268353A1 (en) 2000-06-09 2001-12-17 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
JP4522652B2 (ja) 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド 乱用防止制御放出オピオイド投薬形態
WO2002092059A1 (fr) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Forme posologique d'opioides empechant la consommation abusive
US6555080B1 (en) * 2001-07-13 2003-04-29 Chevron U.S.A. Inc. Using zeolite SSZ-57 for reduction of oxides of nitrogen in a gas stream
AU2002316738B2 (en) 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
MXPA04001210A (es) 2001-08-06 2004-07-08 Euro Celtique Sa Formulaciones de agonista opioide con antagonista liberable y aislado.
CN1652752A (zh) 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 盐酸纳曲酮组合物
AU2003220551A1 (en) 2002-03-26 2003-10-13 Euro-Celtique S.A. Sustained-release gel coated compositions
JP4620355B2 (ja) 2002-04-05 2011-01-26 ユーロ−セルティーク エス．エイ． 活性化合物の持続、不変及び独立放出のためのマトリクス
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
EP1542658B1 (fr) 2002-08-15 2010-12-29 Euro-Celtique S.A. Compositions pharmaceutiques contenant un analgésique opioide
US20050020613A1 (en) 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
CN1703200B (zh) 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
US20050191244A1 (en) 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
US20040110781A1 (en) 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US7524515B2 (en) 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
US20040192715A1 (en) 2003-02-05 2004-09-30 Mark Chasin Methods of administering opioid antagonists and compositions thereof
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20080020028A1 (en) 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
WO2005032555A2 (fr) 2003-09-25 2005-04-14 Euro-Celtique S.A. Combinaisons pharmaceutiques d'hydrocodone et de naltrexone
US20050245557A1 (en) 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
DE10353186A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
DE10353196A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
EP1694386B1 (fr) 2003-12-05 2017-05-03 CareFusion 303, Inc. Analgesie regulee par le patient au moyen d'un systeme de surveillance du patient
WO2005078096A2 (fr) * 2004-02-09 2005-08-25 University Of Massachusetts Oligonucleotides fonctionnels doubles utilises pour reprimer l'expression d'un gene mutant
DK2719378T3 (en) 2006-06-19 2016-10-17 Alpharma Pharmaceuticals Llc pharmaceutical compositions
EP2073797A2 (fr) 2006-10-11 2009-07-01 Alpharma, Inc. Compositions pharmaceutiques
EP2197427A2 (fr) 2007-09-04 2010-06-23 Alpharma, Inc. Compositions pharmaceutiques à plusieurs couches contenant un antagoniste dans la première couche et un agoniste dans la deuxième couche
CA2709905A1 (fr) 2007-12-17 2009-06-25 Alfred Liang Composition d'oxycodone a l'epreuve d'un usage abusif
US20100151014A1 (en) 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
CA2709903A1 (fr) 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Compositions opioides orales comportant un antagoniste opioide
AU2008343267A1 (en) 2007-12-17 2009-07-09 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
MX2013003832A (es) 2010-10-26 2013-10-01 Alpharma Pharmaceuticals Llc Formulaciones y metodos para atenuar la depresion respiratoria inducida por sobredosis de opioides.
SG191872A1 (en) 2011-02-02 2013-08-30 Alpharma Pharmaceuticals Llc Pharmaceutical composition comprising opioid agonist and sequestered antagonist

Also Published As

Publication number Publication date
GEP20053614B (en) 2005-09-26
AU3687701A (en) 2001-08-20
OA12215A (en) 2006-05-09
PT2517710E (pt) 2015-07-01
US20080311198A2 (en) 2008-12-18
US6696088B2 (en) 2004-02-24
US20150182467A1 (en) 2015-07-02
HUP0204229A3 (en) 2006-01-30
DK1299104T3 (da) 2009-08-03
US20040092542A1 (en) 2004-05-13
PT1255547E (pt) 2008-11-24
TWI292317B (en) 2008-01-11
US20180042859A1 (en) 2018-02-15
NO20023729D0 (no) 2002-08-07
US20190350868A1 (en) 2019-11-21
EP1299104A1 (fr) 2003-04-09
ES2415407T3 (es) 2013-07-25
US7682632B2 (en) 2010-03-23
JP5676504B2 (ja) 2015-02-25
US20060039970A1 (en) 2006-02-23
JP5351538B2 (ja) 2013-11-27
BRPI0108380B1 (pt) 2019-10-01
US20170119685A1 (en) 2017-05-04
CZ20022706A3 (cs) 2003-01-15
HK1051487A1 (zh) 2003-08-08
BG65828B1 (bg) 2010-02-26
SI2283842T1 (sl) 2015-07-31
EP2277521A1 (fr) 2011-01-26
US20150231086A1 (en) 2015-08-20
PT2283842E (pt) 2015-07-01
US20140099369A1 (en) 2014-04-10
NO324717B1 (no) 2007-12-03
CN1418098A (zh) 2003-05-14
CZ299991B6 (cs) 2009-01-14
BRPI0108380A8 (pt) 2018-04-24
HU229705B1 (en) 2014-05-28
ES2539945T3 (es) 2015-07-07
DE60138706D1 (de) 2009-06-25
EA004876B1 (ru) 2004-08-26
EP2517710B1 (fr) 2015-03-25
EA200200840A1 (ru) 2003-02-27
NO20023729L (no) 2002-10-04
US8357399B2 (en) 2013-01-22
ME00398B (me) 2011-05-10
HUP0204229A2 (hu) 2003-04-28
AU776666B2 (en) 2004-09-16
US20110097404A1 (en) 2011-04-28
BR0108380A (pt) 2002-10-29
BR0108379A (pt) 2002-11-05
KR20020073542A (ko) 2002-09-26
JP2017048210A (ja) 2017-03-09
KR100552038B1 (ko) 2006-02-20
BRPI0108380B8 (pt) 2021-05-25
US10588865B2 (en) 2020-03-17
US8936812B2 (en) 2015-01-20
SK287107B6 (sk) 2009-12-07
EP2277521B1 (fr) 2015-03-25
US20080305167A2 (en) 2008-12-11
EE05171B1 (et) 2009-06-15
US9456989B2 (en) 2016-10-04
RS50407B (sr) 2009-12-31
US7842311B2 (en) 2010-11-30
AU776904B2 (en) 2004-09-23
US8236351B2 (en) 2012-08-07
JP2016222730A (ja) 2016-12-28
US9278073B2 (en) 2016-03-08
JP6403742B2 (ja) 2018-10-10
CN100563656C (zh) 2009-12-02
EP1299104A4 (fr) 2004-04-21
JP6063427B2 (ja) 2017-01-18
EP2092936A3 (fr) 2009-10-21
IL204761A (en) 2011-10-31
PL358088A1 (en) 2004-08-09
US20130251789A1 (en) 2013-09-26
AP1665A (en) 2006-09-22
SK11342002A3 (sk) 2003-03-04
EE200200437A (et) 2003-12-15
PT1299104E (pt) 2009-07-21
EP2283842A1 (fr) 2011-02-16
WO2001058451A1 (fr) 2001-08-16
NZ520554A (en) 2005-08-26
JP2003522146A (ja) 2003-07-22
ES2539904T3 (es) 2015-07-07
EP2092936B1 (fr) 2013-03-20
US20050095291A1 (en) 2005-05-05
ATE431145T1 (de) 2009-05-15
BG106986A (bg) 2003-04-30
US20050181046A1 (en) 2005-08-18
CY1114063T1 (el) 2016-07-27
HK1135907A1 (en) 2010-06-18
CA2400567C (fr) 2008-01-15
MEP48308A (en) 2011-05-10
UA79069C2 (en) 2007-05-25
US20120288565A1 (en) 2012-11-15
DK2277521T3 (en) 2015-05-26
CN1423559A (zh) 2003-06-11
DK2517710T3 (en) 2015-05-26
US7718192B2 (en) 2010-05-18
HK1056822A1 (en) 2004-03-05
MXPA02007690A (es) 2004-08-23
YU58902A (sh) 2005-11-28
ES2326730T3 (es) 2009-10-19
JP2003522144A (ja) 2003-07-22
HUP0204163A2 (hu) 2003-04-28
SI1299104T1 (sl) 2009-10-31
SI2517710T1 (sl) 2015-07-31
IL151057A (en) 2008-03-20
JP2009138007A (ja) 2009-06-25
AU3687601A (en) 2001-08-20
ES2540103T3 (es) 2015-07-08
SI2277521T1 (sl) 2015-07-31
PT2092936E (pt) 2013-06-20
IL181356A0 (en) 2007-07-04
JP2012176993A (ja) 2012-09-13
EP2283842B1 (fr) 2015-03-25
US7842309B2 (en) 2010-11-30
NO20023728D0 (no) 2002-08-07
US9801828B2 (en) 2017-10-31
JP2015044838A (ja) 2015-03-12
JP2008019280A (ja) 2008-01-31
US20030143269A1 (en) 2003-07-31
MXPA02007686A (es) 2003-03-27
NO20023728L (no) 2002-10-04
CY1109270T1 (el) 2014-07-02
DK2092936T3 (da) 2013-06-17
US20080306104A2 (en) 2008-12-11
CN101703777A (zh) 2010-05-12
US20080311199A2 (en) 2008-12-18
SI2092936T1 (sl) 2013-07-31
DK2283842T3 (en) 2015-05-26
EP1299104B1 (fr) 2009-05-13
US20040186121A1 (en) 2004-09-23
KR20020071032A (ko) 2002-09-11
PL210845B1 (pl) 2012-03-30
PT2277521E (pt) 2015-07-01
AP2002002617A0 (en) 2002-09-30
EP3130338A1 (fr) 2017-02-15
US10350173B2 (en) 2019-07-16
JP2014169306A (ja) 2014-09-18
CA2400567A1 (fr) 2001-08-16
CN101703777B (zh) 2012-11-28
US8586088B2 (en) 2013-11-19
IL181356A (en) 2011-10-31
JP2012158592A (ja) 2012-08-23
WO2001058447A1 (fr) 2001-08-16
US7658939B2 (en) 2010-02-09
IL215132A0 (en) 2011-10-31
EP2517710A1 (fr) 2012-10-31
EP2092936A2 (fr) 2009-08-26

Similar Documents

Publication Publication Date Title
HK1135907A1 (en) Tamper-resistant oral opioid agonist formulations
EG23943A (en) Flash-melt oral dosage formulation
HUP0203204A3 (en) Oral dosage forms
EP1429730A4 (fr) Formulations d'opioides presentant un potentiel reduit pour des utilisations abusives
GB0001621D0 (en) Pharmaceutical compositions
AU6219601A (en) Pharmaceutical compositions
EG24194A (en) 5ht-a-partial agonist pharmaceutical compositions
GB0009584D0 (en) Pharmaceutical compositions
AU8576801A (en) Pharmaceutical compositions
HUP0500638A2 (en) Flashmelt oral dosage formulation
AU1390002A (en) Pharmaceutical compositions
GB0008485D0 (en) Pharmaceutical compositions
GB0016067D0 (en) Oral compositions
GB9923045D0 (en) New oral formulations
GB0009613D0 (en) Pharmaceutical compositions
AU4341401A (en) Opioid formulations
GB0022297D0 (en) Oral compositions
HUP0301891A3 (en) Oral composition
HK1047232A1 (zh) 口服劑型
GB0014497D0 (en) Oral dosage form
PL373799A1 (en) Flashmelt oral dosage formulation
IL132006A0 (en) Stable pharmaceuticl oral dosage forms
GB0000062D0 (en) Pharmaceutical compositions
GB0001337D0 (en) Pharmaceutical compositions
GB0003929D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FF Patent granted
KB20 Patent renewed for 20 years
KB20 Patent renewed for 20 years